Drug intelligence / Profile preview

noliglutide

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Peptides
Administration: Subcutaneous

Overview

Noliglutide (HRS-9499) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Jiangsu Hengrui Medicine for the treatment of metabolic disorders, including obesity and type 2 diabetes. As a GLP-1 analog, it mimics the action of the endogenous incretin hormone, which enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. In the context of weight management, noliglutide promotes satiety and reduces caloric intake by acting on appetite centers in the brain. It is currently undergoing clinical evaluation to assess its efficacy and safety in patients with overweight or obesity, representing a potential therapeutic option in the rapidly evolving landscape of incretin-based therapies.

Other names: noliglutide

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on noliglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on noliglutide.

Explore the full profile